NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · LARGE CAP
Intellia Therapeutics, Inc. NTLA
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$67.7M
▲ 16.9% vs FY2024
EPS · FY25
$-3.81
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-53.5%
Net margin · FY25
-609.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 67.7M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 610 cents on every revenue dollar this year.
Per share
USD -3.81
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-53.5%
Return on equity, FY2025
ROE
Operating margin-651.7%
Net margin-609.9%
Return on assets-40.6%
Each USD of equity lost 53 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+3.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+9.1%
+3.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.12B
Shares outstanding, FY2025
Change, 5 years+75.6%
Change, 10 years—
The share count grew 76% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 842.1M
total assets, end of FY2025
Total assetsUSD 842.1M
EquityUSD 671.4M
CashUSD 155.5M
Current ratio5.08×
Equity funds 80% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.1
0.1
0.0
0.1
0.0
0.1
0.0
0.0
0.0
0.0
·
Operating income $B
−0.4
−0.5
−0.5
−0.5
−0.3
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.4
−0.5
−0.5
−0.5
−0.3
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
·
·
·
0.0
−0.0
Net income $B
−0.4
−0.5
−0.5
−0.5
−0.3
−0.1
−0.5
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−3.81
−5.25
−5.42
−6.16
−3.78
−2.40
−2.11
−1.98
−1.88
−1.42
−51.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−53.5
−54.0
−42.1
−41.7
−34.2
−33.7
−173.1
−29.5
−26.5
−33.5
·
Shares out B
0.12
0.10
0.09
0.09
0.07
0.07
0.05
0.05
0.04
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
33 of 33
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed